Radion Diagnostic And Medical Science Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 13.12%
(FY 2023)
- Ebitda
- Net Worth -68.05%
(FY 2023)
- Total Assets 0.03%
(FY 2023)
About Radion Diagnostic And Medical Science
The Corporate was formerly known as Gungun Jewellers Private Limited. The Company is engaged in the Consumer Goods Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shekhar Agarwal, Naman Aggarwal, and Sanyam Gupta serve as directors at the Company.
- CIN/LLPIN
U36910DL2011PTC221562
- Company No.
221562
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jun 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Radion Diagnostic And Medical Science?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanyam Gupta  | Director | 26-May-2021 | Current |
| Shekhar Agarwal | Director | 23-Aug-2022 | Current |
| Naman Aggarwal | Director | 26-May-2021 | Current |
Financial Performance and Corporate Structure Insights of Radion Diagnostic And Medical Science.
Radion Diagnostic And Medical Science Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 13.12% increase in profit. The company's net worth observed a substantial decline by a decrease of 68.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Radion Diagnostic And Medical Science?
In 2023, Radion Diagnostic And Medical Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Mrm Infotech Private LimitedActive 16 years 4 months
Naman Aggarwal and Sanyam Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Radion Diagnostic And Medical Science?
Unlock and access historical data on people associated with Radion Diagnostic And Medical Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Radion Diagnostic And Medical Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Radion Diagnostic And Medical Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
